Roberto Ferrara, Medical Oncology Researcher at Vita-Salute San Raffaele University, shared a post on X:
“Great debate between Jordi Remon and Stephanie Saw on second-line treatment strategies for EGFR-mutant NSCLC.
The lack of predictive biomarkers remains the elephant in the room.”
You can also read:
Who May Be at Risk of Early Detriment With First-Line Nivolumab Plus Ipilimumab in Metastatic NSCLC?
